drugset / Trial / NCT01956149

Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

NCT01956149

NaSingle-groupOpen-labelTreatment

Summary

Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.

Timeline

Start
2013-09
Primary completion
2017-12
Completion
2018-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabazitaxel Other / unclassified 20 mg/m2 Intravenous

Indications